PvuII and XbaI Polymorphisms of Estrogen Receptor-α and the Results of Estroprogestagen Therapy in Girls with Functional Hypothalamic Amenorrhea - Preliminary Study

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2012 Nov 28

PMID 23185193

Citations 4

Authors

Elzbieta Sowinska-Przepiera

Anhelli Syrenicz

Zbigniew Friebe

Grazyna Jarzabek-Bielecka

Kornel Chelstowski

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of this study was the long-term prospective evaluation of the effects of estroprogestagen (EP) therapy on the bone mineral density (BMD) of girls with functional hypothalamic amenorrhea (FHA) carrying various PvuII and XbaI polymorphisms of ER-α.

Material And Methods: Prospective observation included 84 FHA girls and 50 controls. The FHA patients were subjected to 4-year sequential therapy with 17β estradiol (2 mg from the 2(nd) to 25(th) day of the menstrual cycle) and dydrogesterone (10 mg from the 16(th) to the 25(th) day). Hormonal parameters, serum concentration of the bone fraction of alkaline phosphatase (BALP), urine concentration of cross-linked n-telopeptide of type I collagen (Ntx) and BMD were determined before and after the treatment.

Results: Six-month treatment resulted in a marked increase in estradiol (p = 0.001), testosterone and prolactin levels (p = 0.01 both) and a significant decrease in BALP and Ntx (p = 0.001 both). Patients with the PP polymorphism had significantly lower baseline BMD compared to carriers of other polymorphic variants of PvuII (p = 0.003). A significant increase in BMD was observed throughout the entire therapy period, with no significant differences in the yearly dynamics of BMD changes observed amongst various polymorphic variants and haplotypes of ER-α.

Conclusions: The EP therapy is effective in the treatment of BMD disorders associated with FHA, and treatment results do not depend on PvuII and XbaI polymorphisms of ER-α.

Citing Articles

The influence of ESR1 polymorphisms on selected hormonal, metabolic and mineral balance markers in women with hyperandrogenism.

Uzar I, Bogacz A, Sowinska-Przepiera E, Kotrych K, Wolek M, Sulikowski T Sci Rep. 2022; 12(1):19712.

PMID: 36385124 PMC: 9668905. DOI: 10.1038/s41598-022-17383-w.

Treatments to Prevent Bone Loss in Functional Hypothalamic Amenorrhea: A Systematic Review and Meta-Analysis.

Altayar O, Al Nofal A, Carranza Leon B, Prokop L, Wang Z, Murad M J Endocr Soc. 2017; 1(5):500-511.

PMID: 29264505 PMC: 5686767. DOI: 10.1210/js.2017-00102.

Evaluation of the quality of life of postmenopausal osteoporotic and osteopenic women with or without fractures.

Baczyk G, Samborski W, Jaracz K Arch Med Sci. 2016; 12(4):819-27.

PMID: 27478464 PMC: 4947612. DOI: 10.5114/aoms.2015.55012.

Estrogen receptor β promoter methylation: a potential indicator of malignant changes in breast cancer.

Gao L, Qi X, Hu K, Zhu R, Xu W, Sun S Arch Med Sci. 2016; 12(1):129-36.

PMID: 26925128 PMC: 4754373. DOI: 10.5114/aoms.2016.57588.

References

Seremak-Mrozikiewicz A, Drews K, Bartkowiak-Wieczorek J, Kurzawinska G, Pienkowski W, Spaczynski M . [PvuII genetic polymorphism of estrogen receptor alpha in the group of postmenopausal women with osteopenia and osteoporosis]. Ginekol Pol. 2006; 76(9):679-86. View

Kobayashi N, Fujino T, Shirogane T, Furuta I, Kobamatsu Y, Yaegashi M . Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas. 2002; 41(3):193-201. DOI: 10.1016/s0378-5122(01)00287-0. View

Kostrzak A, Warenik-Szymankiewicz A, Meczekalski B . The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders. Gynecol Endocrinol. 2009; 25(12):799-806. DOI: 10.3109/09513590903209329. View

Warren M, Brooks-Gunn J, Fox R, Holderness C, Hyle E, Hamilton W . Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study. Fertil Steril. 2003; 80(2):398-404. DOI: 10.1016/s0015-0282(03)00660-5. View

Willing M, Sowers M, Aron D, Clark M, Burns T, Bunten C . Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J Bone Miner Res. 1998; 13(4):695-705. DOI: 10.1359/jbmr.1998.13.4.695. View

Sypniewska G, Sobanska I, Pater A, Kedziora-Kornatowska K, Nowacki W . Does serum osteoprotegerin level relate to fragility fracture in elderly women with low vitamin D status?. Med Sci Monit. 2010; 16(2):CR96-101. View

Baczyk G, Opala T, Kleka P . Quality of life in postmenopausal women with reduced bone mineral density: psychometric evaluation of the Polish version of QUALEFFO-41. Arch Med Sci. 2012; 7(3):476-85. PMC: 3258755. DOI: 10.5114/aoms.2011.23415. View

Brodowska A, Starczewski A, Brodowski J, Szydlowska I, Nawrocka-Rutkowska J . The bone mass density in postmenopausal women using hormonal replacement therapy in relation to polymorphism in vitamin D receptor and estrogen receptor genes. Gynecol Endocrinol. 2009; 25(5):315-23. DOI: 10.1080/09513590802630138. View

Carling T, Rastad J, Kindmark A, Lundgren E, Ljunghall S, Akerstrom G . Estrogen receptor gene polymorphism in postmenopausal primary hyperparathyroidism. Surgery. 1998; 122(6):1101-5; discussion 1106. DOI: 10.1016/s0039-6060(97)90214-2. View

10.

Patton G, Hibbert M, Carlin J, Shao Q, ROSIER M, Caust J . Menarche and the onset of depression and anxiety in Victoria, Australia. J Epidemiol Community Health. 1996; 50(6):661-6. PMC: 1060384. DOI: 10.1136/jech.50.6.661. View

11.

Sowers M, Jannausch M, Liang W, Willing M . Estrogen receptor genotypes and their association with the 10-year changes in bone mineral density and osteocalcin concentrations. J Clin Endocrinol Metab. 2004; 89(2):733-9. DOI: 10.1210/jc.2003-030691. View

12.

Munoz M, Morande G, Hervas F, Pozo J, Argente J . The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa. Eur J Endocrinol. 2001; 146(1):45-50. DOI: 10.1530/eje.0.1460045. View

13.

Sowinska-Przepiera E, Andrysiak-Mamos E, Chelstowski K, Adler G, Friebe Z, Syrenicz A . Association between ER-α polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment--a pilot study. J Bone Miner Metab. 2011; 29(4):484-92. DOI: 10.1007/s00774-010-0247-3. View

14.

Tanner J, Whitehouse R, Marshall W, Carter B . Prediction of adult height from height, bone age, and occurrence of menarche, at ages 4 to 16 with allowance for midparent height. Arch Dis Child. 1975; 50(1):14-26. PMC: 1544488. DOI: 10.1136/adc.50.1.14. View

15.

Bonjour J, Chevalley T, Ferrari S, Rizzoli R . The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publica Mex. 2009; 51 Suppl 1:S5-17. DOI: 10.1590/s0036-36342009000700004. View

16.

Liu J, Bill A . Stress-associated or functional hypothalamic amenorrhea in the adolescent. Ann N Y Acad Sci. 2008; 1135:179-84. DOI: 10.1196/annals.1429.027. View

17.

Panico A, Lupoli G, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A . Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life. Med Sci Monit. 2011; 17(8):CR442-448. PMC: 3539612. DOI: 10.12659/msm.881905. View

18.

Katz N, Mazer N . The impact of opioids on the endocrine system. Clin J Pain. 2009; 25(2):170-5. DOI: 10.1097/AJP.0b013e3181850df6. View

19.

Loud K, Gordon C . Adolescent bone health. Arch Pediatr Adolesc Med. 2006; 160(10):1026-32. DOI: 10.1001/archpedi.160.10.1026. View

20.

Havill L, Mahaney M, Binkley T, Specker B . Effects of genes, sex, age, and activity on BMC, bone size, and areal and volumetric BMD. J Bone Miner Res. 2007; 22(5):737-46. DOI: 10.1359/jbmr.070213. View